Phase Genomics, Inc.

3:30 PM - 3:45 PM (PDT), Tuesday, June 14, 2022
Phase Genomics has a mission to enable scientific breakthroughs through technological advances in the genomics. Our strategy focuses on leveraging the unique power of ultra-long-range sequencing tools to solve genomic problems, including assembling and phasing long chromosomes, deconvolving mixed microbial populations, and detecting epigenetic regulatory phenomena. We are a recognized leader in the development and implementation of high-performance computational platforms and tools to unlock the power of ultra-long-range sequencing data for genome scaffolding and metagenomic analysis, with a proven record of enabling deeper insights into the architecture, variation, function, and complexity of genomes, epigenomes, microbiomes and metagenomes. Using this expertise, we have created a platform that leverages our proprietary technology to uncover the potential genomic etiological underpinnings of human disease, enabling translational discoveries that lead to improved health outcomes.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Washington
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
OncoTerra Ultra Long-Range Sequencing Platform
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Phase Genomics, Inc.